Related Experiment Video
Updated: May 23, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
A noval identification of 4 systemic sclerosis - interstitial lung disease subgroups using principal component
Yaqi Zhao1, Baoting Chao2, Wei Xu1,3
1Department of Rheumatology and Immunology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Objective:
Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). It is usually classified by histologic type, but this classification may not fully reflect the clinical phenotypic variation. This study aimed to examine clinical features and aggregate patients with SSc-ILD based on patients' clinical manifestations, High-resolution computed tomography (HRCT) features and specific antibody expression to achieve precise treatment of SSc-ILD with early identification of complications.
Methods:
This study included 103 patients with SSc-ILD. A cluster analysis was performed based on five clinical and serological variables to identify subgroups of patients. The survival rates between obtained clusters and risk factors affecting prognosis were also compared.
Result:
Four clusters were identified in this study: Cluster 1 (n = 23) represented the lymphocytic interstitial pneumonia (LIP) group with LIP as the predominant HRCT characteristic. Cluster 2 (n = 23) was the worst prognosis group, with the highest Warrick score as well as the highest mortality rate. Cluster 3 (n = 20) with all patients having a negative anti-SCL-70 antibody response. Cluster 4 (n = 28) with all patients were positive for the anti-SCL-70 antibody. It was found that albumin was a protective factor for the prognosis of patients with SSC-ILD patients (p = 0.018), whereas age (p = 0.036) and IgM (p = 0.040) were risk factors.
Conclusion:
The results of our cluster analysis indicated that based solely on histologic typing, may not be capturing the full heterogeneity of SSc-ILD patients. In order to identify homogeneous patient groups with a specific prognosis, HRCT features and antibody profiles should be taken into consideration.
